proxyvotesnow.com

Home › Companies › PLIANT THERAPEUTICS INC. › 2023-2024

PLIANT THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and PLIANT THERAPEUTICS INC.’s Form 8-K, filed 2024-06-14 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 176Asset managers
  • 997Fund votes
  • 2024-06-13Meeting date

Proxy season: 2023-2024 2024-2025

Explore PLIANT THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by PLIANT THERAPEUTICS INC.

These tallies are PLIANT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-14 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PLIANT THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-13
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Hoyoung Huh, M.D., Ph.D. 39,087,800---- 12,731,485-- Majority: yes
Elect Director: Darren Cline, MBA 51,397,449---- 421,836-- Majority: yes
Elect Director: David Pyott, MA, MBA 48,388,729---- 3,430,556-- Majority: yes
Proposal 2: The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers 23,479,35328,329,65510,277 ---- Majority: no
Proposal 3: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm 56,628,36810,85362,998 ---- Majority: yes

Source: PLIANT THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-14 — read the filing on EDGAR.

How asset managers voted at the PLIANT THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 176 asset managers that disclosed a PLIANT THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: no

Combines 6 wordings of this item as funds reported it.

45.3% Majority: no · of votes cast

FOR 45.3%AGAINST 54.7%
FOR: 23,479,353AGAINST: 28,329,655

PLIANT THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 23,479,353 for, 28,329,655 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,325,832 outstanding shares: 39% for, 47.0% against (86% of the company cast a for/against vote).

The 175 asset managers below cast 38% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 38%AGAINST 62%
FOR: 37.5%AGAINST: 62.5%NOT VOTED: 0.0%
Largest asset managers voting on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price06,376,878 00Against
Deep Track Capital, LP4,415,3430 00For
Redmile Group, LLC03,499,816 00Against
Vanguard3,480,6310 00For
Laurion Capital Management LP03,474,744 00Against
First Light Asset Management, LLC3,276,9450 00For
Fidelity2,384,609596,221 00For
Capital Group42,754,654 00Against
BlackRock20,1142,708,475 00Against
TRV GP IV, LLC2,132,8670 00For
Polar Capital Holdings Plc01,989,220 00Against
GREAT POINT PARTNERS LLC1,725,9360 00For
FRANKLIN ADVISERS INC01,513,287 00Against
PICTET ASSET MANAGEMENT SA01,189,593 00Against
State Street1,125,40316,975 00For
BESSEMER TRUST Co NATIONAL ASSOCIATION01,059,388 00Against
RA CAPITAL MANAGEMENT, L.P.995,2860 00For
Charles Schwab0861,784 00Against
FRANKLIN STRATEGIC SERIES0829,600 00Against
Granahan Investment Management, LLC0686,064 00Against
Citadel647,3000 00For
GEODE CAPITAL MANAGEMENT, LLC0646,434 00Against
Candriam S.C.A.0548,000 00Against
Bessemer Trust CO of Delaware, N.A.0541,619 00Against
BESSEMER TRUST CO0532,079 00Against

Showing the 25 largest of 175 asset managers. See all 175 in the interactive database.

2. To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 51,397,449WITHHELD: 421,836

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Darren Cline, MBA”): 51,397,449 for, 421,836 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,325,832 outstanding shares: 85% for, 0.7% withheld (86% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (12,940,290 for, 0 against).

FOR 98%
FOR: 12,940,290 (98.1%)ABSTAIN: 248,223 (1.9%)
Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBA” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock1,479,2780 00For
Capital Group1,377,3270 00For
Fidelity903,5420 00For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional00 183,7010Abstain
Jackson National162,5230 1,5260For
Victory Capital160,1270 00For
Equitable99,4890 58,1800For
TIAA146,2320 00For
State Street77,9270 00For
Lincoln Financial74,5160 2,5090For
Russell Investments73,1060 00For
American Century63,6520 00For
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS52,7230 00For
John Hancock48,2000 00For
QUANTITATIVE MASTER SERIES LLC44,2250 00For
AIG/SunAmerica31,4730 00For
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

3. To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 48,388,729WITHHELD: 3,430,556

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Pyott, MA, MBA”): 48,388,729 for, 3,430,556 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,325,832 outstanding shares: 80% for, 6% withheld (86% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (11,266,079 for, 0 against).

FOR 85%ABSTAIN 15%
FOR: 11,266,079 (85.4%)ABSTAIN: 1,922,434 (14.6%)
Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MB” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock00 1,479,2780Abstain
Capital Group1,377,3270 00For
Fidelity881,0980 22,4440For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional00 183,7010Abstain
Jackson National162,5230 1,5260For
Victory Capital160,1270 00For
Equitable10,5200 147,1490Abstain
TIAA146,2320 00For
State Street77,9270 00For
Lincoln Financial74,5160 2,5090For
Russell Investments73,1060 00For
American Century63,6520 00For
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS52,7230 00For
John Hancock48,2000 00For
QUANTITATIVE MASTER SERIES LLC00 44,2250Abstain
AIG/SunAmerica31,4730 00For
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

4. To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD 25%
FOR: 39,087,800WITHHELD: 12,731,485

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Hoyoung Huh, M.D., Ph.D.”): 39,087,800 for, 12,731,485 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,325,832 outstanding shares: 65% for, 21% withheld (86% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (12,257,179 for, 0 against).

FOR 93%7%
FOR: 12,257,179 (92.9%)ABSTAIN: 931,334 (7.1%)
Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., ” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock1,479,2780 00For
Capital Group1,377,3270 00For
Fidelity903,5420 00For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional00 183,7010Abstain
Jackson National00 164,0490Abstain
Victory Capital00 160,1270Abstain
Equitable99,4890 58,1800For
TIAA146,2320 00For
State Street77,8160 1110For
Lincoln Financial47,3000 29,7250For
Russell Investments73,1060 00For
American Century00 63,6520Abstain
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS00 52,7230Abstain
John Hancock27,0820 21,1180For
QUANTITATIVE MASTER SERIES LLC44,2250 00For
AIG/SunAmerica00 31,4730Abstain
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

5. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 56,628,368AGAINST: 10,853

PLIANT THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm”): 56,628,368 for, 10,853 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,325,832 outstanding shares: 94% for, 0.1% against (94% of the company cast a for/against vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (13,188,513 for, 0 against).

FOR 100%
FOR: 13,188,513 (100.0%)
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for th” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock1,479,2780 00For
Capital Group1,377,3270 00For
Fidelity903,5420 00For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional183,7010 00For
Jackson National164,0490 00For
Victory Capital160,1270 00For
Equitable157,6690 00For
TIAA146,2320 00For
State Street77,9270 00For
Lincoln Financial77,0250 00For
Russell Investments73,1060 00For
American Century63,6520 00For
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS52,7230 00For
John Hancock48,2000 00For
QUANTITATIVE MASTER SERIES LLC44,2250 00For
AIG/SunAmerica31,4730 00For
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

Largest PLIANT THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of PLIANT THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 60,325,832 shares outstanding at the time of that meeting.

Top PLIANT THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1T. Rowe Price 10.57%
2Deep Track Capital, LP 7.32%
3Redmile Group, LLC 5.80%
4Vanguard 5.77%
5Laurion Capital Management LP 5.76%
6First Light Asset Management, LLC 5.43%
7Fidelity 4.94%
8Capital Group 4.57%
9BlackRock 4.52%
10TRV GP IV, LLC 3.54%

Reported PLIANT THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

PLIANT THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Deep Track Capital, LP 9.53% DEF14A
FMR LLC 6.57% DEF14A
T. Rowe Price 6.56% 13F
First Light Asset Management LLC 6.02% DEF14A
S F 6.02% 13G
Laurion Capital Management LP 5.94% DEF14A
Morgan Stanley 5.81% 13F
Blue Owl Capital Holdings L.P. 4.98% DEF14A
Vanguard Group 4.60% 13F
JPMorgan Chase 3.53% 13F

Percentages above are of 60,325,832 shares outstanding, as reported by PLIANT THERAPEUTICS INC. on its Form 10-Q dated 2024-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PLIANT THERAPEUTICS INC.’s 10-Q dated 2024-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At PLIANT THERAPEUTICS INC.'s shareholder meeting held 2024-06-13, in the 2023-2024 proxy season, 176 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 997 separate fund positions. On the most widely held item on that ballot — TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER… — FOR was 45.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is not more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: PLIANT THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-14.

PLIANT THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.